ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors

Wen, Yang; Lin, Anqi; Zhu, Weiliang; Wei, Ting; Luo, Peng*; Guo, Linlang*; Zhang, Jian*南方医科大学
Frontiers in Pharmacology2021-6-7DOI: 10.3389/fphar.2021.645862
4被引4阅读
引用收藏
分享

摘要

Background: Lung cancer has always been the most prevalent cancer. Lung adenocarcinoma (LUAD) is the most common lung cancer subtype and has a high tumor mutation rate. In addition to KRAS, EGFR, ALK, HER2, ROS1, and BRAF, which are known to have high mutation rates, we discovered some new mutated genes, such as catenin alpha-2 (CTNNA2), in LUAD patients treated with immune checkpoint inhibitors (ICIs). These mutant genes are potential therapeutic targets for LUAD. Methods: We analyzed a cohort of LUAD patients with somatic mutation and survival data in the Cancer Genome Atlas (TCGA) database and a cohort of LUAD patients receiving immune checkpoint inhibitors with clinical data and whole-exome sequencing (WES) mutation data to evaluate the role of CTNNA2 gene mutation in LUAD. In addition, CIBERSORT was used to analyze the immune characteristics of CTNNA2 wild-type patients and CTNNA2 mutant-type patients, and gene set enrichment analysis (GSEA) was employed for pathway enrichment analysis. The results were verified by downloading data regarding the drug sensitivity of LUAD cell lines from the Genomics of Drug Sensitivity in Cancer (GDSC) database. Results: We found that CTNNA2 mutation was associated with longer overall survival (OS) in LUAD patients. Analysis of the cohort from the Cancer Genome Atlas showed that patients with CTNNA2 mutation had more tumor neoantigens and a greater tumor mutation burden (TMB). Through further analysis of the tumor immune microenvironment, we found that in LUAD patients with CTNNA2 mutations, the gene expression levels of chemokine C-X-C motif chemokine 9 (CXCL9) and granzyme B (GZMB) were elevated, and the gene expression level of inhibitory receptor killer cell immunoglobulin-like receptor 2DL1 (KIR2DL1) was significantly reduced. These alterations might affect gene expression in macrophages, NK cells, and mast cell markers. In addition, LUAD patients with CTNNA2 mutation had a significantly increased number of mutations in DNA damage response (DDR) genes. The drug susceptibility results and gene set enrichment analysis showed that after CTNNA2 mutation occurred, changes were found in the DNA damage response pathway, the phosphoinositide 3-kinase (PI3K) pathway and others, indicating that CTNNA2 mutation can regulate the activation of PI3K and DDR pathways. Conclusion: Our findings provide novel insights into the underlying pathogenesis of LUAD. CTNNA2 mutation can change the immune microenvironment, thereby improving patient prognosis. The results also suggest that CTNNA2 may become a new biomarker and therapeutic target for LUAD in the future.

学科与关键词

关键词
CTNNA2lung adenocarcinomaimmune checkpoint inhibitorsimmune microenvironmentprognosis
相关
加载中…
  • EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma
    Huang, Weimei; Lin, Anqi; Luo, Peng; Liu, Yuchen; Xu, Wentao; Zhu, Weiliang; Wei, Ting; Lyu, Qingwen*; Guo, Linlang*; Zhang, Jian*Cancer Gene Therapy, 2021, 28(7-8): 864-874.被引 26
  • TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Lin, Anqi; Zhang, Hongman; Meng, Hui; Deng, Ze; Gu, Tianqi; Luo, Peng*; Zhang, Jian*Frontiers in Immunology, 2021, 12: 667875.被引 8
  • B Cell Receptor Signaling Pathway Mutation as Prognosis Predictor of Immune Checkpoint Inhibitors in Lung Adenocarcinoma by Bioinformatic Analysis
    Lin, Anqi; Fang, Jianbo; Cheng, Quan; Liu, Zaoqu; Luo, Peng*; Zhang, Jian*Journal of Inflammation Research, 2022, 15.
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Pharmacology
发表日期
2021-06-07
卷期
第 12 卷
页码
645862
DOI
10.3389/fphar.2021.645862
语言
ENGLISH
期刊收录
NSL
期刊等级
2区
成果收录
SCIE

作者

  • W

    Wen, Yang (第一作者)

    southern med univ

  • L

    Lin, Anqi

    southern med univ

查看全部 7 位作者收起作者
  • Z

    Zhu, Weiliang

    southern med univ

  • W

    Wei, Ting

    southern med univ

  • L

    Luo, Peng (通讯)

    southern med univ

  • G

    Guo, Linlang (通讯)

    southern med univ

  • Z

    Zhang, Jian (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417